This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo Nordisk-Metsera deal may raise HSR issues, US FTC says

( November 5, 2025, 22:03 GMT | Official Statement) -- MLex Summary: Novo Nordisk’s proposed acquisition of Metsera may raise serious issues without filing under the Hart-Scott-Rodino Act, the US Federal Trade Commission told Novo Nordisk in a letter. The FTC noted that the deal structure transfers significant rights, benefits and risks to Novo Nordisk prior to the HSR Act review, reducing incentives to continue development, and some of the limitations on Metsera’s conduct prior to Novo’s acquisition of its voting securities raise gun-jumping concerns. Pfizer filed the letter as an exhibit with a Delaware state court in a court challenge to the acquisition. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login